PMID- 26173919
OWN - NLM
STAT- MEDLINE
DCOM- 20160615
LR  - 20150916
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 42
IP  - 10
DP  - 2015 Oct
TI  - Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the 
      treatment of type 2 diabetes mellitus.
PG  - 999-1024
LID - 10.1111/1440-1681.12455 [doi]
AB  - Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic drugs 
      that improve glycaemic control without causing weight gain or increasing 
      hypoglycaemic risk in patients with type 2 diabetes mellitus (T2DM). The eight 
      available DPP-4 inhibitors, including alogliptin, anagliptin, gemigliptin, 
      linagliptin, saxagliptin, sitagliptin, teneligliptin, and vildagliptin, are small 
      molecules used orally with identical mechanism of action and similar safety 
      profiles in patients with T2DM. DPP-4 inhibitors may be used as monotherapy or in 
      double or triple combination with other oral glucose-lowering agents such as 
      metformin, thiazolidinediones, or sulfonylureas. Although DPP-4 inhibitors have 
      the same mode of action, they differ by some important pharmacokinetic and 
      pharmacodynamic properties that may be clinically relevant in some patients. The 
      main differences between the eight gliptins include: potency, target selectivity, 
      oral bioavailability, elimination half-life, binding to plasma proteins, 
      metabolic pathways, formation of active metabolite(s), main excretion routes, 
      dosage adjustment for renal and liver insufficiency, and potential drug-drug 
      interactions. The off-target inhibition of selective DPP-4 inhibitors is 
      responsible for multiorgan toxicities such as immune dysfunction, impaired 
      healing, and skin reactions. As a drug class, the DPP-4 inhibitors have become 
      accepted in clinical practice due to their excellent tolerability profile, with a 
      low risk of hypoglycaemia, a neutral effect on body weight, and once-daily 
      dosing. It is unknown if DPP-4 inhibitors can prevent disease progression. More 
      clinical studies are needed to validate the optimal regimens of DPP-4 inhibitors 
      for the management of T2DM when their potential toxicities are closely monitored.
CI  - (c) 2015 Wiley Publishing Asia Pty Ltd.
FAU - Chen, Xiao-Wu
AU  - Chen XW
AD  - Department of General Surgery, The First People's Hospital of Shunde, Southern 
      Medical University, Shunde, Foshan, Guangdong, China.
FAU - He, Zhi-Xu
AU  - He ZX
AD  - Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue 
      Engineering Research Centre & Sino-US Joint Laboratory for Medical Sciences, 
      Guiyang Medical University, Guiyang, Guizhou, China.
FAU - Zhou, Zhi-Wei
AU  - Zhou ZW
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, University of South 
      Florida, Tampa, FL, USA.
FAU - Yang, Tianxin
AU  - Yang T
AD  - Department of Internal Medicine, University of Utah and Salt Lake Veterans 
      Affairs Medical Centre, Salt Lake City, UT, USA.
FAU - Zhang, Xueji
AU  - Zhang X
AD  - Research Centre for Bioengineering and Sensing Technology, University of Science 
      and Technology Beijing, Beijing, China.
FAU - Yang, Yin-Xue
AU  - Yang YX
AD  - Department of Colorectal Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, Ningxia, China.
FAU - Duan, Wei
AU  - Duan W
AD  - School of Medicine, Deakin University, Waurn Ponds, Vic., Australia.
FAU - Zhou, Shu-Feng
AU  - Zhou SF
AD  - Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue 
      Engineering Research Centre & Sino-US Joint Laboratory for Medical Sciences, 
      Guiyang Medical University, Guiyang, Guizhou, China.
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, University of South 
      Florida, Tampa, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse 
      effects/pharmacokinetics/*pharmacology/therapeutic use
MH  - Humans
MH  - Safety
OTO - NOTNLM
OT  - alogliptin
OT  - anagliptin
OT  - dipeptidyl peptidase-4 inhibitor
OT  - gemigliptin
OT  - linagliptin
OT  - saxagliptin
OT  - sitagliptin
OT  - teneligliptin
OT  - type 2 diabetes
OT  - vildagliptin
EDAT- 2015/07/16 06:00
MHDA- 2016/06/16 06:00
CRDT- 2015/07/16 06:00
PHST- 2014/11/13 00:00 [received]
PHST- 2015/06/11 00:00 [revised]
PHST- 2015/07/06 00:00 [accepted]
PHST- 2015/07/16 06:00 [entrez]
PHST- 2015/07/16 06:00 [pubmed]
PHST- 2016/06/16 06:00 [medline]
AID - 10.1111/1440-1681.12455 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2015 Oct;42(10):999-1024. doi: 
      10.1111/1440-1681.12455.